Leishmaniasis remains a major global health challenge, hampered by an antiquated therapeutic arsenal compromised by toxicity, resistance, and an inability to achieve a sterile cure. The high attrition rate in drug and vaccine development stems from a fundamental disconnect between traditional experimental models and the true biological complexity of the Leishmania life cycle. This review synthesizes recent breakthroughs that have reshaped our understanding of the parasite, arguing that these nonclassical traits are the primary obstacles to effective treatment. We deconstruct the updated life cycle, beginning with the vector stage, which involves reversible differentiation pathways and sexual recombination, generating highly virulent and drug-resistant hybrids. We then analyze the vector inoculum, a complex pro-infectious environment comprising saliva, exosomes, and viral endosymbionts that preconditions the host for infection. At the cellular level, we detail the three pillars of amastigote persistence: metabolic plasticity to survive in nutrient-scarce niches, genomic plasticity (mosaic aneuploidy) to rapidly adapt to drug pressure, and phenotypic plasticity, which generates quiescent persisters tolerant to chemotherapy. Furthermore, we explore the parasite's expanded host-cell tropism, including noncanonical reservoirs such as fibroblasts and adipocytes, which serve as pharmacological sanctuaries. Finally, we discuss how targeting these biological complexities, eradicating persisters, neutralizing the vector inoculum, and reaching cryptic reservoirs are prerequisites for the next generation of drugs and vaccines. This review posits that the era of ″one bug, one drug″ is over and that the path to a sterile cure for leishmaniasis lies in a biology-driven, precision-medicine approach.
Martín‐Escolano et al. (Thu,) studied this question.